Cellectis S.A. (NASDAQ: CLLS)
$2.16
+0.0700 ( +3.35% ) 40.5K
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
Market Data
Open
$2.16
Previous close
$2.09
Volume
40.5K
Market cap
$217.20M
Day range
$2.09 - $2.27
52 week range
$0.96 - $3.77
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 2 | May 06, 2024 |
6-k | Quarterly Reports | 3 | May 03, 2024 |
20-f | Annual reports | 149 | Apr 29, 2024 |
6-k | Quarterly Reports | 2 | Apr 22, 2024 |
6-k | Quarterly Reports | 2 | Apr 10, 2024 |
6-k | Quarterly Reports | 2 | Apr 08, 2024 |
6-k | Quarterly Reports | 2 | Jan 16, 2024 |
6-k | Quarterly Reports | 4 | Dec 22, 2023 |
6-k | Quarterly Reports | 2 | Dec 22, 2023 |
6-k | Quarterly Reports | 6 | Dec 05, 2023 |